IGNIS THERAPEUTICS
Ignis Therapeutics is a innovative therapies in the field of central nervous system.
IGNIS THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2019-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Status:
Active
Total Funding:
180 M USD
Similar Organizations
Aratana Therapeutics
Aratana Therapeutics develops innovative therapies for the animal health industry.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
Memo Therapeutics
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Employees Featured
Investors List
WTT Investment
WTT Investment investment in Series A - Ignis Therapeutics
6 Dimensions Capital
6 Dimensions Capital investment in Series A - Ignis Therapeutics
Ruentex Group
Ruentex Group investment in Series A - Ignis Therapeutics
KB Investment
KB Investment investment in Series A - Ignis Therapeutics
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series A - Ignis Therapeutics
Goldman Sachs
Goldman Sachs investment in Series A - Ignis Therapeutics
Mubadala Petroleum
Mubadala Petroleum investment in Series A - Ignis Therapeutics
More informations about "Ignis Therapeutics"
Ignis Therapeutics
翼思生物于2020年末成立，是一家专注于脑疾病的生物科技公司，致力于将前沿科学转化为可惠及患者的创新解决方案。现有产品管线20个，主要聚焦在癫痫、日间过度思睡、失眠、帕金森病 …See details»
Ignis Therapeutics - Crunchbase Company Profile
Ignis Therapeutics may be growing as it has secured a significant investment from Mubadala, indicating strong investor confidence. The company also …See details»
Innovation & Development | Ignis Therapeutics
*Ignis holds global rights to IGS-RD-001, 002, 004, 011, 012, as well as IGS-E0301~E0308. *IGS-RD-001, 002, 004, 011, 012 are in-house developed candidates of Ignis. Products. Cenobamate *Cenobamate has not yet been …See details»
Ignis Therapeutics - BIO International Convention 2025
Ignis Therapeutics. Biotech or pharma, therapeutic R&D Ignis is a CNS-focused biotech with specialized expertise and full-cycle capabilities from discovery to clinical to commercialization. …See details»
Ignis Therapeutics - Funding, Financials, Valuation & Investors
Ignis Therapeutics is a innovative therapies in the field of central nervous system. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. …See details»
Ignis Therapeutics Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Ignis Therapeutics of West Bay Road, GRAND CAYMAN. Get the latest business insights from Dun …See details»
Ignis Therapeutics (Suzhou) Limited - Drug pipelines, Patents, …
Clinical Trials associated with Ignis Therapeutics (Suzhou) Limited. NCT06103825 / Completed Phase 3. ... The statistics for drugs in the Pipeline is the current organization and its …See details»
Ignis Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials ...
Mar 26, 2024 Explore Ignis Therapeutics Ltd. with its drug pipeline, therapeutic area, technology platform, .See details»
SK biopharmaceuticals files NDA for cenobamate in China through …
Dec 4, 2024 From left, Ignis Therapeutics CEO Eileen Long, SK biopharmaceuticals CEO Lee Dong-hoon, and 6D Capital CEO Leon Chen pose at a joint ceremony at Ignis Therapeutics' …See details»
SK Biopharm, 6D establish biotech company in China
Nov 11, 2021 SK Biopharm said it launched a biotech company Ignis Therapeutics (Ignis), with 6 Dimensions Capital (6D), a healthcare investment firm based in Shanghai, to build a new drug development and commercialization …See details»
Investment | Ignis Therapeutics
On the same day, Ignis also announced a strategic partnership with SK Biopharmaceuticals, a leading global CNS pharmaceutical company. 6 Dimensions Capital is a global company led …See details»
Ignis Therapeutics （HK） Limited - Drug pipelines, Patents
Explore Ignis Therapeutics （HK） Limited with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 14 news, Disease Domain:Nervous System Diseases, Immune …See details»
Ignis Therapeutics - Contacts, Employees, Board Members
Organization. Ignis Therapeutics . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. Ignis Therapeutics has 1 …See details»
IGNIS Therapeutics (Shanghai) Co., Ltd. - synapse.zhihuiya.com
了解IGNIS Therapeutics (Shanghai) Co., Ltd. (翼思生物医药（上海）有限公司)公司的药物管线，治疗领域，技术平台，以及它的14篇新闻，疾病领域:神经系统疾病，免疫系统疾病，内分 …See details»
Ignis Therapeutics (Suzhou) Limited - synapse.zhihuiya.com
了解Ignis Therapeutics (Suzhou) Limited (翼思生物医药（苏州）有限公司)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验，疾病领域:神经系统疾病，免疫系统疾病，感染，内 …See details»
Ignis Therapeutics - Drug pipelines, Patents, Clinical trials - Synapse
Explore Ignis Therapeutics with its drug pipeline, therapeutic area, technology platform, 10 news, Drug:Solriamfetol Hydrochloride. ... The statistics for drugs in the Pipeline is the current …See details»
Conditions | Ignis Therapeutics
According to estimates by the World Health Organization (WHO), the global lifetime prevalence of schizophrenia is 3.8‰~8.4‰. A national epidemiological study found that the lifetime …See details»
Ignis Therapeutics （HK） Limited - synapse.zhihuiya.com
了解Ignis Therapeutics （HK） Limited (翼思生物醫藥（香港）有限公司)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验, 29篇新闻，疾病领域:神经系统疾病，免疫系统疾病， …See details»
New study results reinforce Tagrisso as the backbone therapy for …
Mar 25, 2025 New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as …See details»
IGS-RD-004 - Drug Targets, Indications, Patents - Synapse
Mar 20, 2025 IGS-RD-004, Initially developed by IGNIS Therapeutics (Shanghai) Co., Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Nervous System ...See details»